Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.76 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA4 | P22748 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20010530 | 0.94 | KMT2A (0.88) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL14417945 | 0.92 | KMT2A (0.86) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL4239479 | 0.92 | ENPP2 (0.88) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL17946434 | 0.91 | KMT2A (0.83) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL5010625 | 0.89 | KMT2A (0.80) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL31667420 | 0.88 | KMT2A (0.78) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL5009943 | 0.88 | HPGD (0.78) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL5012350 | 0.88 | HPGD (0.78) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL5010921 | 0.87 | HPGD (0.76) | KMT2AMEN1HPGDENPP2CA1 | |
| SCHEMBL3439592 | 0.86 | ENPP2 (1.00) | KMT2AMEN1HPGDENPP2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319098-B2 | 1,3-dioxoisoindole derivatives having selective antagonism of T-type calcium channel | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-01-15 | — | — | US | disclosed |
| US-20070259867-A1 | 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2007-11-08 | — | — | US | disclosed |
| EP-0173207-B1 | POLYAMIDE-IMIDES WITH MODIFIED END GROUPS | BAYER AG (DE) | 1990-09-19 | — | — | EP | disclosed |
| US-4829140-A | Polyamidimides having modified end groups | BAYER AKTIENGESELLSCHAFT (DE) | 1989-05-09 | — | — | US | disclosed |
| EP-0173207-A2 | Polyamide-imides with modified end groups | BAYER AG (DE) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259867-A1 | 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL | CACNA1I, CACNA1G, CACNA1H | KMT2A 4804/4885MEN1 959/4885HPGD 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.